slipped after it amended its manufacturing agreement with Cobra Biologics. Under the new pact, Cobra will complete only one biologics license application batch of the active ingredient for AA4500, Auxilium's injectable enzyme. Shares were down 0.4% at $15.88.
edged higher after it received regulatory approval for its generic equivalent to an infection-fighting
The Food and Drug Administration approval covers the antibacterial combination treatment consisting of ampicillin and sulbactam for injection, a generic equivalent to Pfizer's Unasyn. This marks the 10th approval Abraxis has received this year, the company says. The FDA is currently reviewing an additional 26 drug applications from the company. Shares of Abraxis gained 0.3% to $26.87.
Teva Pharmaceutical Industries
rose after it received tentative approval for its generic version of
migraine drug Imitrex.
Teva's version of the drug, also known as sumatriptan succinate, is expected to receive final approval in February 2009, after Glaxo's patent on the drug expires. In the 12 months ended this past September, the branded medication brought in $910 million in sales, Teva says. Teva gained 0.5% to $32.55.
was higher after it received regulatory clearance for a clot-removing device. The device, dubbed the AngioJet Xpeedior catheter, was approved by the Food and Drug Administration for the removal of blood clots in the upper and lower extremities. The Xpeedior is the first approved device for use in thrombectomies in peripheral veins, the company says.
The stock was up 9.6% to $12.51.